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Mihály Herczeg1 & Anikó Borbás1
One critical part of the synthesis of heparinoid anticoagulants is the creation of the L-iduronic acid 
building block featured with unique conformational plasticity which is crucial for the anticoagulant 
activity. Herein, we studied whether a much more easily synthesizable sugar, the 6-deoxy-L-talose, 
built in a heparinoid oligosaccharide, could show a similar conformational plasticity, thereby can be 
a potential substituent of the L-idose. Three pentasaccharides related to the synthetic anticoagulant 
pentasaccharide idraparinux were prepared, in which the L-iduronate was replaced by a 6-deoxy-
L-talopyranoside unit. The talo-configured building block was formed by C4 epimerisation of the 
commercially available L-rhamnose with high efficacy at both the monosaccharide and the disaccharide 
level. The detailed conformational analysis of these new derivatives, differing only in their methylation 
pattern, was performed and the conformationally relevant NMR parameters, such as proton-proton 
coupling constants and interproton distances were compared to the corresponding ones measured in 
idraparinux. The lack of anticoagulant activity of these novel heparin analogues could be explained by 
the biologically not favorable 1C4 chair conformation of their 6-deoxy-L-talopyranoside residues.
Venous thromboembolism is a major cause of mortality and morbidity in the western countries, and epidemi-
ological studies indicate that the aging of the population will increase the incidence of this illness worldwide1,2. 
Medical therapy for venous thromboembolism has been limited to the use of the thrombin inhibitor heparin and 
the vitamin K antagonists 4-hydroxycoumarins (e.g. warfarin) over 70 years since the 1930’s3. Then, the 21st cen-
tury opened a new era for the anticoagulant treatment. The first breakthrough was the approval of fondaparinux, 
the synthetic analogue of the antithrombin-binding pentasaccharide domain of heparin as a new antithrombotic 
drug. Fondaparinux is an indirect, selective factor Xa inhibitor possessing a higher safety profile and a longer 
elimination half-life compared to the animal-originated heparin products4. Just a few years later new oral antico-
agulant drugs, the direct thrombin inhibitor dabigatran etexilate and the direct factor Xa inhibitors rivaroxaban, 
apixaban and edoxaban have been approved for clinical use, revolutionising the anticoagulant therapy5. Although 
these new oral anticoagulants have major pharmacologic advantages over vitamin K antagonists, they also have 
drawbacks and are not approved for some clinical situations6–8. These data predict that the classic anticoagulant 
drugs, particularly the heparin derivatives will continue to be important medicines for antithrombotic therapy9.
In the field of heparinoid anticoagulants, current research focuses on unmet issues such as low oral bioavail-
ability of heparin10, lack of specific antidote for low molecular weight heparins11, and chemoenzymatic produc-
tion of heparin oligosaccharides12–15. Furthermore, many research efforts have been devoted to the development 
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of highly efficient synthetic routes to the outstanding anticoagulant pentasaccharides fondaparinux16–18 and 
idraparinux19,20 as well as the preparation of various analogues of the antithrombin-binding pentasaccharide unit 
of heparin as novel anticoagulant candidates21–25.
For a successful synthesis of heparin oligosaccharides a number of factors must be considered such as access 
to L-idose or L-iduronic acid (IdoA) unit, the choice of uronic acid or the corresponding non-oxidised precur-
sor as building blocks, stereochemical control in glycosylation, suitable protecting-group strategy and efficient 
assembly of the backbone sequence26,27. A range of synthetic approaches have been described to generate hepari-
noids including solid-supported synthesis28, modular approach29,30 and nonglycosylating strategy19. To avoid the 
inherent low reactivity and base-sensitivity of uronic acid donors, typically the corresponding glycopyranosides 
are used as glycosyl donors and the formation of the uronic acid can be performed at the disaccharide level31 or 
by TEMPO-mediated late-stage oxidation at the higher oligosaccharide level20,32.
However, each strategy toward chemical synthesis of heparin oligosaccharides faces the same difficulty: the 
lengthy, laborious and low-yielding synthesis of the L-iduronic acid building block, which is a critically important 
structural component for the anticoagulant activity. Despite recent progress33–35, the short and efficient synthesis 
of an orthogonally protected L-idose or iduronic acid glycosyl donor useful for heparinoid synthesis remained 
unmet. We envisioned that replacing the IdoA with a more easily available sugar unit would solve the problem 
and L-talopyranuronic acid could be a good candidate as a potential structural substituent. It is known, that 
a unique conformational plasticity of the L-iduronic acid, shift the 1C4 - 2SO equilibrium to the bioactive 2SO 
skew-boat conformation, is required for the antithrombotic activity36 and it was also shown, that its conforma-
tion is regulated by the sulphation pattern of nearby saccharides14,37. We assume that L-talose, which only differs 
from L-idose in the C3 configuration, can also adopt the required skew-boat conformation. Moreover, an attrac-
tive, short synthesis of L-talopyranosyl thioglycoside, ready for glycosylation has been developed recently38. This 
method, based on iridium-catalyzed CH-activation of the corresponding 6-deoxy derivative39 can potentially uti-
lize in the synthesis of the L-talopyranuronic acid-containing heparinoid oligosaccharides. As a first step towards 
this goal we decided to prepare idraparinux-analogue pentasaccharides in which the iduronic acid unit is substi-
tuted by a 6-deoxy-L-talopyranoside, a very easily accessible 6-deoxy-L-hexose (Fig. 1). Idraparinux (1) is a syn-
thetic anticoagulant pentasaccharide based on the heparin binding domain possessing a higher anti-Xa activity 
and a longer half-life than the synthetic anticoagulant drug fondaparinux4. Being a fully O-sulfated, O-methylated 
non-glycosaminoglycan analogue, its synthesis is easier than that of fondaparinux, which makes it an ideal model 
compound. Although the 6-deoxy-L-talopyranoside lacks the biologically important carboxylate moiety, it is 
suitable for studying the conformational behavior of a talopyranose built in the highly sulphated pentasaccharide. 
Herein, we report the synthesis and NMR-based conformational analysis of three idraparinux analogue penta-
saccharides (2–4) in which the iduronic acid unit (unit G) is substituted by a 6-deoxy-L-talopyranoside moiety 
(Fig. 1).
Results
Over the last years, we have developed several new methods for the synthesis of idraparinux20,40,41. The most 
efficient strategy involves a 3 + 2 coupling of a FGH trisaccharide acceptor and a DE disaccharide donor, and 
application of acetyl groups to mask the hydroxyls to be methylated and benzyl ethers to protect the hydroxyls 
to be sulfated in the final product20. We applied the same strategy for the synthesis of compounds 2–4. The 
preparation of the orthogonally protected 6-deoxy-L-talopyranosyl glycosyl donor 9 was accomplished from the 
Figure 1. The synthetic anticoagulant pentasaccharide idraparinux (1) and the planned analogues 2–4 
containing a 6-deoxy-L-talopyranoside instead of the L-iduronic acid (unit G).
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commercially available and cheap 6-deoxy L-hexose, L-rhamnose (Fig. 2). Peracetylation and thioglycosylation 
of the starting L-rhamnose gave 542, which was converted to the L-talo-configured 639 by the well-established 
C4 epimerization method involving oxidation followed by stereoselective reduction of the corresponding 
2,3-O-acetalated rhamnose derivative43. Protection of the 4-OH by (2-naphthyl)methylation gave 7 in 93% yield. 
Finally, the isopropylidene protecting group was replaced by ester groups by deacetalation followed by acetylation 
to result in the 6-deoxy-L-talopyranoside donor 9 having a C2 participating group capable of ensuring the desired 
1,2-trans-selectivity upon glycosylation.
Glycosylation of acceptor 1044 with donor 9 in the presence of N-iodosuccinimide (NIS) and trif-
luoromethanesulfonic acid (TfOH) led to the formation of the expected 1,2-trans-α-linked disaccha-
ride 11 in 96% yield (Fig. 3). Oxidative cleavage of the 4′-O-(2-naphthyl)methyl (NAP) group using 
2,3-dichloro-5,6-dicyanobenzoquinone (DDQ)45 gave the disaccharide acceptor 12. This disaccharide was iso-
lated together with a small amount of the 2′,4′-di-O-acetyl byproduct due to the undesired acetyl-migration 
occurred during the column chromatographic purification. Condensation of acceptor 12 with donor 1320 in the 
presence of NIS and trimethylsilyl trifluoromethanesulfonate (TMSOTf) resulted in an inseparable 1:1 mixture of 
the α- and β-linked trisaccharides 14 in a moderate yield (Fig. 3). The complete lack of stereoselectivity of the gly-
cosylation was surprising because analogous reactions of 13 with either an L-idose20 or an L-iduronate25 acceptor 
proceeded with exclusive α-selectivity. After an oxidative cleavage of the temporary NAP-protecting group of 14 
by DDQ, the desired trisaccharide acceptor 15 was isolated successfully, albeit with low yield.
In order to avoid side reactions and increase the yield, the assembly of the FGH trisaccharide was attempted 
by using the isopropylidenated 6-deoxy-L-talopyranoside derivative 7 as the donor in the first glycosylation step 
(Fig. 4). To our delight, the glycosylation with donor 7, equipped with a non-participating group at C2, proceeded 
with exclusive 1,2-trans-selectivity providing the desired α-linked disaccharide 17 as the only product. Although 
the yield of 17 was moderate upon NIS-TMSOTf promotion, it was significantly increased by changing the Lewis 
acid in the promoter system to silver triflate (AgOTf). The role of the hindered base sym-collidine in the coupling 
Figure 2. Synthesis of the 6-deoxy-L-talopyranoside donor (NAP: (2-naphthyl)methyl).
Figure 3. Synthesis of the FGH trisaccharide acceptor 15 by applying the 2,3-di-O-acetylated 6d-talose donor 9.
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reactions was to protect the acid-labile isopropylidene group against the acidic conditions of glycosylation. The 
4′-OH of 17 was freed by oxidative cleavage of the NAP group using DDQ and the obtained disaccharide acceptor 
18 was glycosylated with donor 13 in the presence of a NIS-AgOTf promoter system. Pleasingly, the condensation 
reaction occurred with complete α-selectivity affording the desired FGH trisaccharide 19 in 60% yield. Finally, 
removal of the NAP-ether from the terminal glucose unit gave acceptor 20 in 63% yield.
Although most difficulties of the first synthetic route to the acceptor FGH was overcame by changing the ester 
protected 6-deoxy-L-talopyranosyl building block 9 for the 2,3-acetal-protected donor 7 in the second route, 
we were not satisfied with the overall yield of this latter procedure. Therefore, we tested a third route for the 
preparation of trisaccharide FGH in which the phenylthio-α-L-rhamnopyranoside derivative 5 was used as the 
talose-precursor building block and the C4 epimerization of this unit was carried out at the disaccharide level 
(Fig. 5). Condensation of the L-rhamnose donor 5 and acceptor 10 led to the exclusive formation of the α-linked 
disaccharide 21 in 98% yield. After Zemplén deacetylation and a subsequent isopropylidenation, the two-step C4 
epimerization, involving oxidation with pyridinium chlorochromate (PCC) followed by stereoselective reduc-
tion using NaBH4, proceeded with high efficacy affording the 6-deoxy-L-talose-containing disaccharide 18 in an 
excellent 71% overall yield from 21 via 22 and 23. Disaccharide 18 was glycosylated with 13, as described in the 
previous route. The 2′,3′-O-isopropylidene acetal moiety of 19 was changed to ester groups by acidic hydrolysis of 
the acetal group followed by acetylation of the obtained 24 to give 14 in 90% yield over the two steps. Oxidative 
removal of the 4″-O-NAP ether provided the desired FGH acceptor 15 in 77% yield.
The assembly of the targeted pentasaccharides was carried out by coupling of the trisaccharide acceptors 15 
and 20 with the non-glucuronide type DE disaccharide donor 2546 (Fig. 6). According to our previously estab-
lished strategy, we planned the oxidation of the glucose precursor E into D-glucuronic acid at the pentasaccharide 
level20,24,41. Condensation reaction of the isopropylidene-containing trisaccharide acceptor 20 and donor 25 upon 
NIS-TMSOTf activation provided the needed pentasaccharide 26 together with its diol derivative 27 formed by 
Figure 4. Synthesis of the FGH trisaccharide acceptor 20 by using the 2,3-O-isopropylidenated 7 as an α-
selective donor.
Figure 5. Improved synthesis of FGH acceptor 15.
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partial loss of the acetal group under the acidic conditions of the coupling. The products were unified by cleavage 
of the isopropylidene group of 26 to give diol 27 which was then acetylated to obtain the fully protected pentasac-
charide 28 in 74% yield. The advantage of this protecting group pattern was that all hydroxyls to be methylated 
or freed in the final products were masked with the same acetate ester groups while the hydroxyls to be sulphated 
were protected in form of benzyl esters. Condensation of the 2′,3′-di-O-acetylated trisaccharide acceptor 15 and 
donor 25 provided a direct access to pentasaccharide 28. While the coupling showed only moderate efficacy upon 
NIS-TMSOTf promotion, changing the promoter system to NIS-TfOH compound 28 was formed in an excellent 
90% isolated yield.
Towards synthesis of the final products 3 and 4, the first transformation at the pentasaccharide level was the 
removal of the temporary (2-naphthyl)methyl group from unit E followed by (2,2,6,6-tetramethylpiperidin-1-yl)
oxyl (TEMPO) and [bis(acetoxy)iodo]benzene (BAIB) mediated oxidation47,48 of the freed primary hydroxyl 
group of 29 to produce the glucuronate-containing pentasaccharide 30 in form of a sodium salt (Fig. 7). 
Then, catalytic hydrogenolysis gave the debenzylated 31 in 94% yield, sulphation of which using excess SO3/
Et3N complex in DMF afforded, after treatment with Dowex Na+ ion-exchange resin, the partially acetylated 
idraparinux-analogue final product 3 as an octasodium salt in 77% yield. The cleavage of the acetyls with the use 
of 3 M aqueous NaOH solution resulted in 4, another idraparinux-analogue derivative containing free hydroxyl 
groups at units E and G.
Transformation of compound 28 into the fully O-methylated and O-sulphated final product required a dif-
ferent pathway. It is known that uronic acid residues are prone to suffer β-elimination in the basic conditions of 
the etherification46,49. Therefore, prior to the oxidative formation of the glucuronide residue, compound 28 was 
deacetylated under Zemplén conditions and the obtained 32 was methylated in the presence of methyl iodide and 
sodium hydride. After the efficient methyl etherification, compound 33 was converted into the glucoronate deriv-
ative 35 in high yield by NAP-deprotection followed by TEMPO-BAIB oxidation of the freed hydroxyl at unit E. 
Finally, the hydroxyl groups to be sulphated were debenzylated by catalytic hydrogenolysis to give 36 in 86% yield. 
Subsequently, simultaneous O-sulphation of the seven freed hydroxyls was achieved with high efficacy using 
excess SO3/Et3N to give, after treatment with Dowex Na+ ion exchange resin, the target compound 2 in 91% yield.
The structure of all synthesized pentasaccharide derivatives was corroborated by 1H and 13C NMR spectros-
copy. The unambiguous assignment of NMR resonances was achieved by combined use of 1D and 2D homo- and 
heteronuclear NMR spectroscopic methods, including COSY, TOCSY, ROESY, HSQC and HMBC experiments.
In heparin-related oligosaccharides the L-iduronic acid and L-iduronic acid 2-sulphate residues exist in a 
dynamic equilibrium of the 1C4, 2SO and 4C1 conformers where the chair 1C4 and the skew-boat 2SO are the pre-
dominant conformational forms (Fig. 8A)14,15,36. Each conformer has a unique set of three bond proton-proton 
coupling constants 3J(H,H) which have recently been calculated by Liu and co-workers14 using Amber 14 with 
GLYCAM06 parameter50 (Table 1, calculated values). To investigate the conformational behavior of the func-
tionally most critical unit G and to assess the relative population of the skew-boat (2SO) conformer, known to be 
essential for binding to antithrombin, the structurally relevant 3J(H,H) couplings were measured for the novel 
Figure 6. The [2 + 3] block syntheses by using trisaccharides 20 and 15 as the acceptors.
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talo-derivatives (2–4) and compared to the calculated values as well as to the corresponding data of idraparinux 140, 
which was used as reference compound in the present study (Table 1).
The distributions of conformers were also studied by 1H-1H NOE analysis. The NOE cross peak intensities 
are uniquely sensitive to detect the presence of the skew-boat conformer due to the significant difference in 
the atomic distance between H2 and H5 in the 2SO conformational form (2.6 Å), compared with the 1C4 (4.0 Å) 
(Fig. 8A). The shorter H2-H5 interproton distance in the 2SO conformer offers a stronger NOE intensity. Liu and 
co-workers demonstrated14 that together with the analysis of 3J(H,H) couplings, the ratio of H2-H5 and H4-H5 
NOE intensities can be used to estimate the conformer population of the L-iduronic acid residue.
As shown in Table 1, the 3J(1,2) and 3J(2,3) values for each talo-analogue are considerably smaller than the 
ones measured in idraparinux, thus suggesting that the relative population of the biologically favorable skew 
boat (2SO) conformer is reduced in the talo-derivatives and the conformational equilibrium is shifted towards the 
Figure 7. Synthesis of the idraparinux-analogue pentasaccharides 2–4 with various substitution pattern at units 
E and G.
Figure 8. (A) Dominant conformational forms of the IdoA residue present in heparin-related oligosaccharides 
and calculated distances between H2 and H5, as well as H4 and H514; R = H or SO3H. (B) Predominant 
conformation of unit G in pentasaccharide 1 and pentasaccharides 2–4.
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functionally less preferred 1C4 chair conformer (Fig. 8B). The analysis of H2-H5 and H4-H5 NOE intensity ratios 
(Table 1) also confirms this shift of the conformational equilibrium. The small values of NOE ratios, ranging 
between 0.1 and 0.2, suggest that a major 1C4 chair conformer with longer atomic distance between H2 and H5, 
correspondingly with weaker H2-H5 NOE crosspeak, indeed exists in D2O solution. (The interproton distances 
within unit G estimated from the volume integrals of ROESY cross peaks are summarized in Table S2).
Finally, the inhibitory activities of pentasaccharides 2–4 towards blood-coagulation proteinase Xa were 
determined by using Berichrom heparin assay (Table S1). Unfortunately, almost complete loss of the factor 
Xa-inhibitory activity was observed.
Discussion
Heparin and heparinoid anticoagulants exert their anticoagulant activity by binding and activation of antithrom-
bin (AT) which is an endogenous inhibitor of serine proteases in the coagulation cascade51. It has been known 
that plasticity of the L-iduronic acid unit of heparin, an easy shift from the equilibrium state of the preferred 
1C4 and 2SO conformations to the 2SO skew-boat form, is crucial for the stabilization of the activated confor-
mation of AT36,52. A detailed knowledge has been accumulated on how the sulphation pattern of neighbouring 
sugar residues and the sulphation of iduronic acid itself influence the conformational preference of this pyranosyl 
unit14,15,37,53,54. However, the precise structural requirements of the conformational plasticity is not known and 
it has not been studied whether other L-sugars, incorporated in a heparin structure, can adopt the bioactive 2SO 
conformation. Considering the complicated synthesis of the iduronate building block, the possible substitution 
of this unit by a more easily available monosaccharide, possessing the required conformational plasticity, would 
be of great importance.
In this work, we replaced the iduronate residue of the synthetic anticoagulant idraparinux by a 6-deoxy- 
L-talopyranose, which is the most easily available L-hexose epimer of L-idose, and studied the conforma-
tional behavior and biological activity of the obtained pentasaccharides. Beside the closest, fully O-sulphated 
and fully O-methylated analogue of idraparinux, a partially methylated and a methylated/acetylated deriv-
ative was also synthesized. The assembly of pentasaccharide skeleton was accomplished by coupling a 
6-deoxy-L-talopyranoside-containing trisaccharide acceptor to a non-glucuronide disaccharide donor and the 
glucose precursor was oxidized to the required glucuronide at the pentasaccharide level. The key building block, 
the 6-deoxy-L-talose-containing trisaccharide FGH was prepared through three different reaction paths, the 
shortest and most efficient route was when a phenylthio-α-L-rhamnopyranoside was used as the precursor build-
ing block and its conversion to the talo-configured unit G was performed at the disaccharide level.
While we successfully simplified and shortened the preparation of a heparinoid anticoagulant by replacing 
the synthetically most demanding unit, the biological activity was almost completely lost. The conformational 
analysis of pentasaccharides 2–4, based on 1H NMR ROESY measurements, revealed that the critically impor-
tant unit G predominantly populated the functionally less preferred 1C4 chair conformation. It was also shown 
that differences in the methylation pattern of the pentasaccharides had no effects on the conformer distribution 
of the talo-residue. The observed loss of the biological activities could be attributed to the lack of the essential 
carboxylic moiety of unit G as well as to the less abundance of the bioactive 2SO conformer in the conformational 
equilibrium. We assume, that conversion of the 6-deoxy-L-talose residue to L-taluronic acid using established 
methods38,47 and introduction of a 2-O-sulphate moiety, which is present in the natural AT-binding sequence, 
might push the conformational equilibrium of unit G toward the crucial 2SO form.
It is very important to note that although literature data show correlation between the affinity of heparin 
oligosaccharides and the relative population of the 2SO form of iduronic acid in solution55, recent results of Liu, 
Guerrini and co-workers14,15 revealed that predominant population of the 2SO skew boat conformer of iduronic 
acid in free form is not a prerequisite for the activation of AT. They demonstrated that a synthetic heparin hex-
asaccharide, iduronate residue of which is displayed 73% of 1C4 conformer in solution, can efficiently activate 
antithrombin and the iduronic acid adopts a 2SO conformation when bound to AT. These results indicate that 
although conformational analysis is very important, the biological test can not be avoided before making a final 
judgment on the anticoagulant activity of a compound. Further studies to find the aurea mediocritas, to simplify 
the structure and synthesis of heparin oligosaccharides to an extent that the compounds could keep the biological 
activity, are under way.
Calculated values Locked conformation[a,b] Measured values for unite G
4C1 1C4 2SO 1 2 3 4
3J(1,2) 7.85 1.35 5.55 2.6 <1.0 1.6 1.6
3J(2,3) 8.03 2.04 8.48 5.5 3.0 3.6 3.2
3J(3,4) 8.50 2.19 4.82 2.2 3.0 3.7 not determined due to signal overlap
Ratio of H2-H5 and 
H4-H5 NOE signals 0.03 0.05 0.53 0.5 0.1 0.1 <0.2
Table 1. 3J(H,H) couplings [Hz] and ratio of pertinent NOE intensities calculated for the L-iduronic-acid 
residue in its locked conformations together with the relevant 3J(H,H) [Hz] and NOE values measured for 
residue G in 1–4. [a]Calculated 3J(H,H) values (Hz) for locked 2SO, 1C4 and 4C1 conformers14. [b]Calculated ratio 
of NOE H2-H5 and H4-H5 signal intensities for pure 2SO, 1C4 and 4C1 conformers14.
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Methods
Optical rotations were measured at room temperature on a Perkin-Elmer 241 automatic polarimeter. TLC analy-
sis was performed on Kieselgel 60 F254 (Merck) silica-gel plates with visualization by immersing in a sulfuric-acid 
solution (5% in EtOH) followed by heating. Column chromatography was performed on silica gel 60 (Merck 
0.063–0.200 mm) and Sephadex LH-20 (Sigma-Aldrich, bead size: 25–100 mm). Organic solutions were dried 
over MgSO4 and concentrated under vacuum. One- (1D) and two-dimensional (2D) 1H, 13C, COSY, ROESY 
and HSQC spectra were recorded on Bruker Avance II 400 (1H: 400 MHz; 13C: 100.28 MHz), Avance II 500 (1H: 
500.13 MHz; 13C: 125.76 MHz) and Avance Neo 700 (1H: 700.25 MHz; 13C: 176.08 MHz) spectrometers at 25 °C. 
Chemical shifts are referenced to SiMe4 or sodium 3-(trimethylsilyl)-1-propanesulfonate (DSS, = 0.00 ppm for 1H 
nucleus) and to the solvent signals (CDCl3: δ = 77.00 ppm, (CD3OD: δ = 49.15 ppm for 13C nucleus). MALDI-TOF 
MS analyses of the compounds were carried out in the positive reflektron mode using a BIFLEX III mass spec-
trometer (Bruker, Germany) equipped with delayed-ion extraction. 2,5-Dihydroxybenzoic acid (DHB) was used 
as matrix and F3CCOONa as cationising agent in DMF. ESI-TOF MS spectra were recorded by a microTOF-Q 
type QqTOFMS mass spectrometer (Bruker) in the positive ion mode using MeOH as the solvent. Elemental 
analysis was performed on an Elementar Vario MicroCube (CHNS) instrument. The anti-factor Xa activity of 
2–4 was determined in vitro by Berichrom® Heparin chromogenic assay on a Siemens BCS-XP automated coag-
ulometer (Siemens, Marburg, Germany), using pooled normal human plasma (see Supporting Infromation). 
Pentasaccharides 2–4 were tested in at least 3 different concentrations (final concentration range of 250–1000 μg/mL) 
using a pentasaccharide (fondaparinux/Arixtra) calibrator from Diagnostica Stago (Asnieres, France).
Octa-sodium [methyl (2,3,4-tri-O-methyl-6-O-sulfonato-α-D-glucopyranosyl)-(1→4)-(2,3-di-O- 
methyl-β-D-glucopyranosyl-uronate)-(1→4)-(2,3,6-tri-O-sulfonato-α-D-glucopyranosyl)-(1→4)-
(2,3-di-O-methyl-6-deoxy-α-L-talopyranosyl)-(1→4)-(2,3,6-tri-O-sulfonato-α-D-glucopyranoside)] (2)
A solution of compound 36 (120 mg, 0.125 mmol) in dry DMF (7.0 mL) was treated with SO3/Et3N (792 mg, 
4.371 mmol). After stirring for 48 h at 50 °C, the reaction mixture was neutralized with a saturated aqueous solu-
tion of NaHCO3 (1.836 g, 21.85 mmol) and the resulting mixture was concentrated. The crude product was treated 
with Dowex ion-exchange resin (Na+) and purified by column chromatography on Sephadex G-25 (H2O) to give 
compound 2 (192 mg, 92%) as a white foam. [α]D + 55.0 (c 0.14, H2O); R f 0.36 (7:6:1 CH2Cl2/MeOH/H2O); 1H 
NMR (400 MHz, D2O) δ = 5.71 (d, J = 3.2 Hz, 1H, H-1-F), 5.45 (d, J = 3.6 Hz, 1H, H-1-D), 5.15 (d, J = 2.7 Hz, 
2H, H-1-H, H-1-G), 4.70–4.61 (m, 3H, H-1-E, H-3-F, H-5-G), 4.57 (t, J = 9.2 Hz, 1H, H-3-H), 4.41–4.29 (m, 5H, 
H-2-H, H-2-F, H-6a,b-F, H-6a-H), 4.27–4.22 (m, 2H, H-6b-H, H-6a-D), 4.18 (s, 1H, H-4-G), 4.11 (d, J = 10.9 Hz, 
1H, H-6b-D), 4.04–4.00 (m, 3H, H-4-F, H-5-F, H-5-H), 3.92 (t, J = 9.4 Hz, 1H, H-4-H), 3.89–3.85 (m, 2H, H-4-E, 
H-5-D), 3.79 (s, 1H, H-3-G), 3.72 (d, J = 9.7 Hz, 1H, H-5-E), 3.62–3.45 (m, 3H, H-2-G, H-3-E, H-3-D), 3.34–3.29 
(m, 2H, H-2-D, H-4-D), 3.25 (t, J = 8.0 Hz, 1H, H-2-E), 3.61, 3.60, 3.58, 3.56, 3.54, 3.48, 3.47, 3.46 (8 x s, 24H, 
8 x OCH3), 1.31 (d, J = 6.5 Hz, 3H, CH3 talose) ppm; 13C NMR (100 MHz, D2O) δ = 175.9 (1C, COONa), 102.1 
(1C, C-1-E), 98.0 (2C, C-1-H, C-1-G), 96.9 (1C, C-1-D), 96.2 (1C, C-1-F), 86.3 (1C, C-3-E), 83.8 (1C, C-2-E), 
82.6 (1C, C-2-D), 81.2 (1C, C-3-D), 78.8 (1C, C-4-D), 78.2 (1C, C-3-G), 77.9 (1C, C-2-G), 77.6 (1C, C-5-E), 76.7 
(1C, C-3-H), 76.2 (1C, C-2-F), 76.0 (1C, C-2-H), 75.8 (1C, C-3-F), 75.2 (1C, C-4-E), 73.9 (1C, C-4-F), 73.4 (1C, 
C-4-H), 71.2 (1C, C-4-G), 70.9 (1C, C-5-F), 69.9 (1C, C-5-H), 69.5 (1C, C-5-D), 68.6 (1C, C-5-G), 67.3, 66.9 (2C, 
C-6-F, C-6-H), 66.7 (1C, C-6-D), 61.2, 61.0, 60.8, 60.3, 59.8, 59.7, 57.6 (7C, 7 x OCH3), 56.3 (1C, C-1-H-OCH3), 
17.1 (1C, CH3 talose) ppm; MS (ESI-TOF): m/z calcd for C38H58Na5O47S7, [M-3Na]3− 534.990; found: 534.989 
[M-3Na]3−; elemental analysis calcd (%) for C38H58Na8O47S7 (1673.924); C, 27.25; H, 3.49; S, 13.40; found: C, 
27.37; H, 3.55; S, 13.48.
Octa-sodium [methyl (2,3,4-tri-O-methyl-6-O-sulfonato-α-D-glucopyranosyl)-(1→4)-(2,3-di-O- 
acetyl-β-D-glucopyranosyl-uronate)-(1→4)-(2,3,6-tri-O-sulfonato-α-D-glucopyranosyl)-(1→4)-
(2,3-di-O-acetyl-6-deoxy-α-L-talopyranosyl)-(1→4)-(2,3,6-tri-O-sulfonato-α-D-glucopyranoside)] (3)
A solution of compound 31 (78 mg, 0.073 mmol) in dry DMF (4.0 mL) was treated with SO3/Et3N (461 mg, 
2.545 mmol). After stirring for 48 h at 50 °C, the reaction mixture was neutralized with a saturated aqueous solu-
tion of NaHCO3 (1.069 g, 12.72 mmol). The resulting mixture was concentrated. The crude product was treated 
with Dowex ion-exchange resin (Na+) and purified by column chromatography on Sephadex G-25 (H2O) to 
give compound 3 (100 mg, 77%) as a white foam. [α]D + 14.0 (c 0.10, H2O); R f 0.40 (7:6:1 CH2Cl2/MeOH/H2O); 
1H NMR (400 MHz, D2O) δ = 5.35 (d, J = 2.9 Hz, 1H, H-1-F), 5.30 (t, J = 9.2 Hz, 1H, H-3-E), 5.27 (d, J = 1.8 Hz, 
1H, H-3-G), 5.21 (d, J = 3.8 Hz, 1H, H-1-D), 5.16 (d, J = 3.5 Hz, 2H, H-1-H, H-2-G), 5.04 (s, 1H, H-1-G), 4.97 
(d, J = 8.0 Hz, 1H, H-1-E), 4.91 (d, J = 8.9 Hz, 1H, H-2-E), 4.82–4.72 (m, 2H, H-3-F, H-5-G), 4.59 (t, J = 9.5 Hz, 
1H, H-3-H), 4.45 (dd, J = 2.2 Hz, J = 11.3 Hz, 1H, H-6a-F), 4.39–4.34 (m, 2H, H-2-H, H-6b-F), 4.31–4.27 (m, 
3H, H-2-F, H-6a-D, H-6a-H), 4.24–4.22 (m, 1H, H-5-F), 4.18–4.13 (m, 4H, H-4-E, H-4-G, H-6b-H, H-6b-D), 
4.05–4.01 (m, 2H, H-4-F, H-5-H), 3.96–3.88 (m, 3H, H-4-H, H-5-E, H-5-D), 3.63 (s, 3H, C-3-D-OCH3), 3.58 
(s, 3H, C-4-D-OCH3), 3.54 (t, J = 9.6 Hz, 1H, H-3-D), 3.48 (s, 3H, C-2-D-OCH3), 3.46 (s, 3H, C-1-H-OCH3), 
3.32 (t, J = 9.8 Hz, 1H, H-4-D), 3.29 (dd, J = 3.9 Hz, J = 9.9 Hz, 1H, H-2-D), 2.17, 2.14 (2 x s, 12H, 4 x CH3 OAc), 
1.38 (d, J = 6.6 Hz, 3H, CH3 talose) ppm; 13C NMR (100 MHz, D2O) δ = 175.0, 174.6, 174.5, 173.9, 173.8 (5C, 
COONa, 4 x Cq OAc), 99.7 (1C, C-1-E), 98.5 (1C, C-1-G), 98.4 (1C, C-1-F), 98.3 (1C, C-1-D), 98.2 (1C, C-1-H), 
83.4 (1C, C-3-D), 81.0 (1C, C-2-D), 79.0 (1C, C-4-D), 77.8 (1C, C-5-E), 77.2 (1C, C-4-E), 76.9 (1C, C-2-F), 76.7 
(1C, C-3-F), 76.5 (1C, C-3-H), 76.3 (1C, C-3-F), 76.2 (1C, C-2-H), 76.0 (1C, C-4-G), 74.6 (1C, C-4-F), 73.6 (1C, 
C-2-E), 73.2 (1C, C-4-H), 71.1 (1C, C-5-F), 69.9 (2C, C-5-H, C-5D), 68.4 (1C, C-2-G), 68.3 (1C, C-3-G), 68.2 
(1C, C-5-G), 66.8 (2C, C-6-D, C-6-H), 66.7 (1C, C-6-F), 61.1 (1C, C-3-D-OCH3), 60.9 (1C, C-4-D-OCH3), 60.4 
(1C, C-2-D-OCH3), 56.3 (1C, C-1-H-OCH3), 21.7, 21.6, 21.4, 21.2 (4C, 4 × CH3 OAc), 16.8 (1C, CH3 talose) ppm; 
MS (ESI-TOF): m/z calcd for C42H58Na4O51S7, [M-4Na]4− 423.490; found: 423.491 [M-4Na]4−; elemental analysis 
calcd (%) for C42H58Na8O51S7 (1785.92); C, 28.23; H, 3.27; S, 12.56; found: C, 28.37; H, 3.34; S, 12.63.
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Octa-sodium [methyl (2,3,4-tri-O-methyl-6-O-sulfonato-α-D-glucopyranosyl)-(1→4)-(β-D- 
glucopyranosyl-uronate)-(1→4)-(2,3,6-tri-O-sulfonato-α-D-glucopyranosyl)-(1→4)-(6-deoxy- 
α-L-talopyranosyl)-(1→4)-(2,3,6-tri-O-sulfonato-α-D-glucopyranoside)] (4)
To a solution of compound 3 (50 mg, 0.028 mmol) in MeOH (1.2 mL) a solution of NaOH (3 M, 600 μL) was 
added at 0 °C. When complete conversion of the starting material into a main spot had been observed by TLC 
analysis (24 h at room temperature), the mixture was neutralized with AcOH and all volatiles were evaporated. 
The crude product was purified by column chromatography on Sephadex G-25 (H2O) to give compound 4 (35 mg, 
78%) as a white foam. [α]D + 62.5 (c 0.10, H2O); R f 0.69 (7:3 MeCN/H2O); 1H NMR (400 MHz, D2O) δ = 5.69 (d, 
J = 3.9 Hz, 1H, H-1-F), 5.64 (d, J = 3.7 Hz, 1H, H-1-D), 5.15 (d, J = 3.5 Hz, 1H, H-1-H), 5.10 (d, J = 0.5 Hz, 1H, 
H-1-G), 4.71–4.66 (m, 2H, H-3-F, H-5-G), 4.64 (d, J = 7.9 Hz, 1H, H-1-E), 4.58 (t, J = 9.3 Hz, 1H, H-3-H), 4.47 
(dd, J = 3.9 Hz, J = 9.4 Hz, 1H, H-2-F), 4.42–4.26 (m, 5H, H-2-H, H-6a-F, H-6a-D, H-6a,b-H), 4.23–4–21 (m, 1H, 
H-6b-F), 4.13 (d, J = 9.8 Hz, 1H, H-6b-D), 4.06–4.00 (m, 5H, H-3-G, H-4-G, H-4-F, H-5-H, H-5-F), 3.95–3.85 
(m, 4H, H-2-G, H-4-E, H-4-H, H-5-D), 3.79 (d, J = 10.0 Hz, 1H, H-5-E), 3.73 (t, J = 8.8 Hz, 1H, H-3-E), 3.60 (s, 
3H, C-3-D-OCH3), 3.57 (s, 3H, C-4-D-OCH3), 3.54–3.51 (m, 1H, H-3-D), 3.52 (s, 3H, C-2-D-OCH3), 3.46 (s, 3H, 
C-1-H-OCH3), 3.42 (dd, J = 8.2 Hz, J = 9.1 Hz, 1H, H-2-E), 3.37–3.31 (m, 2H, H-2-D, H-4-D), 1.32 (d, J = 6.5 Hz, 
3H, CH3 talose) ppm; 13C NMR (100 MHz, D2O) δ = 102.1 (1C, C-1-E), 101.2 (1C, C-1-G), 98.1 (1C, C-1-H), 97.9 
(1C, C-1-F), 96.7 (1C, C-1-D), 82.3 (1C, C-3-D), 81.2 (1C, C-2-D), 78.9 (2C, C-4-D, C-4-F), 78.0 (1C, C-5-E), 
77.5 (1C, C-3-E), 77.1 (1C, C-4-E), 76.5 (2C, C-3-H, C-3-F), 76.1 (1C, C-2-H), 75.6 (1C, C-2-F), 74.4 (1C, C-2-E), 
73.8 (1C, C-4-H), 73.6 (1C, C-3-G), 71.0 (1C, C-4-G), 70.5 (1C, C-2-G), 70.0 (1C, C-5-H), 69.6 (1C, C-5D), 68.3 
(1C, C-5-G), 67.7 (1C, C-5-F), 67.2 (1C, C-6-H), 66.9 (2C, C-6-D, C-6-F), 61.0 (1C, C-3-D-OCH3), 60.8 (1C, 
C-4-D-OCH3), 59.0 (1C, C-2-D-OCH3), 56.3 (1C, C-1-H-OCH3), 17.7 (1C, CH3 talose) ppm; MS (ESI-TOF): 
m/z calcd for C34H50Na3O47S7, [M-4Na]4− 300.586; found: 300.585 [M-4Na]4−; elemental analysis calcd (%) for 
C34H50Na8O47S7 (1617.87); C, 25.22; H, 3.11; S, 13.86; found: C, 25.31; H, 3.18; S, 13.94.
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